Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, efficacy and exposure to TRM-1 in
subjects with relapsed or refractory Non-Hodgkin's Lymphoma (NHL).